The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Highlights in multiple myeloma from ASH 2024: anito-cel, bispecifics, and novel agents
In this interview, Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, shares his highlights in multiple myeloma (MM) from the ASH 2024 meeting, stating that the presentation of data on CAR T-cell therapies, bispecific antibodies, and other novel agents has moved the needle forward in the treatment of myeloma. Dr Fonseca highlights the encouraging results of teclistamab, both as frontline therapy and as a maintenance strategy following transplant, and mentions some exciting novel agents, such as a P300 inhibitor. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
The ASH 2024 meeting has been quite exceptional. Before coming here I was not sure what to expect, but we saw data being presented that further moves the needle forward towards better treatment of myeloma. You know, we were all excited to see updates regarding some of the ongoing clinical trials, particularly with CAR-T’s. And for the first time we’ll see a robust report on one of the new CAR T’s of anito-cel, so I think everyone’s very excited to see that...
The ASH 2024 meeting has been quite exceptional. Before coming here I was not sure what to expect, but we saw data being presented that further moves the needle forward towards better treatment of myeloma. You know, we were all excited to see updates regarding some of the ongoing clinical trials, particularly with CAR-T’s. And for the first time we’ll see a robust report on one of the new CAR T’s of anito-cel, so I think everyone’s very excited to see that.
Having said that the data that has been presented with regards to bispecific antibodies is pretty remarkable. There are two presentations that caught my eye. One was the use of teclistamab for frontline therapy for patients who are transplant eligible, where the numbers are very small, but all patients became MRD negative. So I think those levels of response are really unprecedented. Likewise, we saw a study using teclistamab as maintenance therapy, post-stem cell transplant, and once more, all patients became MRD negative. Now the caveat with this is small numbers, but this could be a total paradigm change in how we approach frontline therapy for myeloma. And those numbers holding, that means that then a substantial number of patients might have a very durable disease control. So I’m very excited about that.
We saw some updates with regards to belantamab as well too. People are interested in this because it’s an active agent. And one of the most interesting ones is the upfront use of belantamab, where it was shown that the combination is highly efficacious, perhaps even better than what we’re able to achieve currently with daratumumab. Of course, there’s trade-offs because there’s a toxicity with a keratopathy. So we’ll have to wait and see further where that goes.
There’s some new molecules. There’s some degraders that are being presented, as well as a P300 inhibitor, which seems to have promising activity. So all in all, I think it was a wonderful meeting.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Celgene, Bristol Myers Squibb, Bayer, Amgen, Janssen, Kite, a Gilead company, Merck Sharp & Dohme, Juno Therapeutics, Takeda, AbbVie, Aduro Biotech, Sanofi, OncoTracker: Honoraria; Patent for FISH in MM – ~$2000/year: Patents & Royalties: Patent for FISH in MM – ~$2000/year; AbbVie, Adaptive, Amgen, Apple, Bayer, BMS/Celgene, Gilead, GSK, Janssen, Kite, Karyopharm, Merck Sharp & Dohme, Juno Therapeutics, Takeda, Arduro Biotech, Oncotracker, Oncopeptides, Pharmacyclics, Pfizer, RA Capital, Regeneron, Sanofi: Consultancy; Antengene: Membership on an entity’s Board of Directors or advisory committees.
